EA201171305A1 - Терапевтическое средство при моторных нарушениях - Google Patents

Терапевтическое средство при моторных нарушениях

Info

Publication number
EA201171305A1
EA201171305A1 EA201171305A EA201171305A EA201171305A1 EA 201171305 A1 EA201171305 A1 EA 201171305A1 EA 201171305 A EA201171305 A EA 201171305A EA 201171305 A EA201171305 A EA 201171305A EA 201171305 A1 EA201171305 A1 EA 201171305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
prophylaxis
agent
movement disorder
motor
Prior art date
Application number
EA201171305A
Other languages
English (en)
Other versions
EA027308B1 (ru
Inventor
Нориаки Уесака
Такаси Савада
Томоюки Канда
Original Assignee
Киова Хакко Кирин Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201171305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Киова Хакко Кирин Ко., Лтд. filed Critical Киова Хакко Кирин Ко., Лтд.
Publication of EA201171305A1 publication Critical patent/EA201171305A1/ru
Publication of EA027308B1 publication Critical patent/EA027308B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Представлено средство для лечения и/или профилактики моторных нарушений; средство для лечения и/или профилактики, где нарушение движений представляет собой экстрапирамидный синдром; средство для лечения и/или профилактики, где нарушение движений представляет собой брадикинезию, нарушение походки, дистонию, дискинезию или позднюю дискинезию; средство для лечения и/или профилактики, где нарушение движений представляет собой побочный эффект терапии L-DOPA и/или агонистом дофамина; и т.п., причем каждое содержит производное тиазола, представленное формулой (I), в которой Rпредставляет собой арил и т.п. и Rпредставляет собой пиридил и т.п., или его фармацевтически приемлемую соль в качестве активного ингредиента.
EA201171305A 2009-04-28 2010-04-28 Терапевтическое средство при моторных нарушениях EA027308B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009109434 2009-04-28
PCT/JP2010/057563 WO2010126082A1 (ja) 2009-04-28 2010-04-28 運動障害治療剤

Publications (2)

Publication Number Publication Date
EA201171305A1 true EA201171305A1 (ru) 2012-05-30
EA027308B1 EA027308B1 (ru) 2017-07-31

Family

ID=43032226

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171305A EA027308B1 (ru) 2009-04-28 2010-04-28 Терапевтическое средство при моторных нарушениях

Country Status (25)

Country Link
US (4) US20120101101A1 (ru)
EP (2) EP3378860A1 (ru)
JP (1) JP5687617B2 (ru)
KR (2) KR20160087926A (ru)
CN (3) CN104606190B (ru)
AU (1) AU2010242375B2 (ru)
BR (1) BRPI1011768A8 (ru)
CA (1) CA2760048C (ru)
CL (1) CL2011002650A1 (ru)
EA (1) EA027308B1 (ru)
ES (1) ES2678119T3 (ru)
HK (1) HK1169115A1 (ru)
HU (1) HUE038319T2 (ru)
IL (1) IL215963A (ru)
MX (1) MX345169B (ru)
MY (1) MY166649A (ru)
NZ (1) NZ596362A (ru)
PL (1) PL2433938T3 (ru)
PT (1) PT2433938T (ru)
SG (2) SG10201401698QA (ru)
TR (1) TR201809003T4 (ru)
TW (1) TWI548411B (ru)
UA (1) UA112957C2 (ru)
WO (1) WO2010126082A1 (ru)
ZA (1) ZA201108665B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA013249B1 (ru) * 2003-12-26 2010-04-30 Киова Хакко Кирин Ко., Лтд. Производные тиазола
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529916A (ja) * 2001-04-09 2004-09-30 ニューロサーチ、アクティーゼルスカブ パーキンソン病の治療において神経栄養活性化合物と組み合わせたアデノシンａ２ａレセプターアンタゴニスト
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
ES2686123T3 (es) * 2002-01-28 2018-10-16 Kyowa Hakko Kogyo Co., Ltd Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento
EA013249B1 (ru) * 2003-12-26 2010-04-30 Киова Хакко Кирин Ко., Лтд. Производные тиазола
EA200700707A1 (ru) * 2004-09-22 2007-08-31 Х. Лундбекк А/С Производные 2-ациламинотиазола
AU2006234627C1 (en) * 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
ES2385702T3 (es) * 2005-06-07 2012-07-30 Kyowa Hakko Kirin Co., Ltd. Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
TWI457125B (zh) 2005-08-02 2014-10-21 睡眠障礙之治療劑
US20090005568A1 (en) 2005-08-18 2009-01-01 Pharmacopeia Drug Discovery, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
ATE457988T1 (de) 2006-06-26 2010-03-15 Schering Corp A2a-adenosin-rezeptor-antagonisten
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
CA2731573C (en) 2008-07-23 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Selective adenosine a2a receptor antagonists useful in the treatment and prevention of migraine

Also Published As

Publication number Publication date
CN102414209A (zh) 2012-04-11
AU2010242375A1 (en) 2011-12-08
PL2433938T3 (pl) 2018-09-28
CN102414209B (zh) 2015-01-28
US20150225417A1 (en) 2015-08-13
HUE038319T2 (hu) 2018-10-29
MX345169B (es) 2017-01-19
US10407440B2 (en) 2019-09-10
ES2678119T3 (es) 2018-08-09
AU2010242375B2 (en) 2015-11-05
EA027308B1 (ru) 2017-07-31
PT2433938T (pt) 2018-07-13
TR201809003T4 (tr) 2018-07-23
TW201103541A (en) 2011-02-01
US20170275296A1 (en) 2017-09-28
US9714257B2 (en) 2017-07-25
JPWO2010126082A1 (ja) 2012-11-01
US20120101101A1 (en) 2012-04-26
CN104606190B (zh) 2018-01-19
IL215963A (en) 2016-06-30
ZA201108665B (en) 2018-11-28
SG175368A1 (en) 2011-11-28
MY166649A (en) 2018-07-18
HK1169115A1 (en) 2013-01-18
CA2760048A1 (en) 2010-11-04
CL2011002650A1 (es) 2012-06-15
JP5687617B2 (ja) 2015-03-18
SG10201401698QA (en) 2014-06-27
NZ596362A (en) 2014-03-28
CN104606190A (zh) 2015-05-13
UA112957C2 (uk) 2016-11-25
WO2010126082A1 (ja) 2010-11-04
BRPI1011768A2 (pt) 2016-03-29
EP2433938A4 (en) 2013-03-27
KR20120023019A (ko) 2012-03-12
EP3378860A1 (en) 2018-09-26
TWI548411B (zh) 2016-09-11
IL215963A0 (en) 2012-01-31
KR101692091B1 (ko) 2017-01-02
KR20160087926A (ko) 2016-07-22
BRPI1011768A8 (pt) 2018-01-02
EP2433938B1 (en) 2018-04-18
US20190359631A1 (en) 2019-11-28
CN104557904A (zh) 2015-04-29
CA2760048C (en) 2016-04-26
MX2011011269A (es) 2011-11-18
EP2433938A1 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
EA201171305A1 (ru) Терапевтическое средство при моторных нарушениях
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
TN2016000489A1 (en) Carboxamide derivatives.
TN2016000491A1 (en) Carboxamide derivatives.
SA519402090B1 (ar) مثبطات انتقائية لـ hdac6، وطريقة تحضيرها، واستخدامها
NZ727142A (en) 2-acylaminothiazole derivative or salt thereof
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
PH12019501566A1 (en) Amide compounds and use thereof
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
MX345264B (es) Derivado de azol.
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent